Avadel Pharmaceuticals Set to Shine at Healthcare Conference
Avadel Pharmaceuticals plc (Nasdaq: AVDL), known for its dedication to improving patient care through innovative biopharmaceutical solutions, is gearing up for a pivotal moment at the Jefferies London Healthcare Conference. This significant event will take place on a Wednesday morning, featuring a fireside chat with the company's management team at 7:30 a.m. GMT / 2:30 a.m. ET.
What to Expect at the Conference
The conference serves as a platform for Avadel’s leadership to engage with investors, analysts, and the healthcare community, shedding light on the company’s ongoing projects and future directions. Participants can look forward to a perspective on how Avadel plans to tackle some of the pressing medical challenges faced by patients today.
Live Webcast and Archived Content
For those unable to attend in person, a live webcast of the event will be available, along with an archived recording. These resources are crucial for investors and interested parties wishing to stay informed about the company’s development and initiatives in transforming medicines to improve lives.
Company Overview
Avadel Pharmaceuticals has carved a niche in the biopharmaceutical industry with their innovative approaches to medication development. Their flagship product, LUMRYZ™, holds the distinction of being the first and only once-at-bedtime oxybate approved by the U.S. Food and Drug Administration (FDA). This product targets cataplexy and excessive daytime sleepiness (EDS) in individuals aged 7 years and older who are living with narcolepsy.
Our Commitment to Innovation
Avadel remains deeply committed to addressing the complex challenges patients encounter with existing treatment options. The company not only focuses on creating effective medications but also strives to enhance the overall quality of life for its users.
Connecting with Avadel
Investors and media representatives interested in learning more about Avadel’s strategic initiatives can reach out directly to the designated contacts. Investor relations inquiries should be directed to Courtney Mogerley at Precision AQ, while media queries can be addressed to Lesley Stanley at Real Chemistry.
Contact Information
Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
Frequently Asked Questions
What is the purpose of the Jefferies London Healthcare Conference?
The conference aims to connect healthcare companies with investors to discuss innovations and market strategies.
What product is Avadel Pharmaceuticals known for?
Avadel Pharmaceuticals is well-known for LUMRYZ™, a medication for narcolepsy that has received FDA approval.
How can I access the conference webcast?
The webcast will be available on Avadel’s Investor Relations website and can be accessed live or as an archived event for 90 days.
Who should I contact for media inquiries regarding Avadel?
For media inquiries, you can contact Lesley Stanley at Real Chemistry.
Is Avadel focused solely on narcolepsy treatments?
No, while LUMRYZ™ addresses narcolepsy, Avadel Pharmaceuticals is committed to developing various innovative solutions aimed at addressing broader medical challenges.
